PCM
LGND icon

Penn Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Penn Capital Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.1M Sell
95,456
-3,392
-3% -$671K 1.48% 14
2025
Q4 		$18.7M Sell
98,848
-8,434
-8% -$1.62M 1.49% 12
2025
Q3 		$19M Sell
107,282
-13,102
-11% -$1.95M 1.46% 11
2025
Q2 		$13.7M Sell
120,384
-455
-0.4% -$48.6K 1.18% 41
2025
Q1 		$12.7M Buy
120,839
+16,409
+16% +$1.86M 1.24% 37
2024
Q4 		$11.2M Buy
104,430
+4,212
+4% +$476K 1.1% 45
2024
Q3 		$10M Buy
+100,218
New +$10.1M 0.92% 51

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Penn Capital Management's LGND Position: Q1 2026 in Review

Penn Capital Management reduced its Ligand Pharmaceuticals (LGND) stake by 3.4% in Q1 2026, selling an estimated $671K and leaving 95,456 shares worth $19.1M. The position accounts for 1.48% of the portfolio, ranked #14.

Penn Capital Management first reported a position in LGND in Q3 2024 and has held it in 7 quarters since. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Penn Capital Management held 95,456 shares of Ligand Pharmaceuticals worth $19.1M as of Q1 2026.
  • Penn Capital Management sold 3,392 Ligand Pharmaceuticals shares in Q1 2026, an estimated $671K.
  • Ligand Pharmaceuticals made up 1.48% of Penn Capital Management's portfolio in Q1 2026, its #14 holding.
  • Penn Capital Management first reported a position in Ligand Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Penn Capital Management's 13F filing for Q1 2026, filed 7 May 2026.